CoChat

Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy‐proven Japanese non‐alcoholic fatty liver disease patients

Open access
Ito, Takanori, Ishigami, Masatoshi, Ishizu, Yoji, Kuzuya, Teiji, Honda, Takashi, Hayashi, Kazuhiko, Nishimura, Daisaku, Toyoda, Hidenori, Kumada, Takashi, Goto, Hidemi, Hirooka, Yoshiki · 2019 · Journal of Gastroenterology and Hepatology
Cited by 41

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background and Aim: The fibrosis stage of non‐alcoholic fatty liver disease (NAFLD) is closely associated with long‐term prognosis, including liver‐related mortality. However, it is not yet clear whether noninvasive fibrosis markers can predict the incidence of non‐liver‐related complications in Japanese NAFLD. In this study, we clarified the prognosis of NAFLD patients, including non‐liver‐related diseases, based on hepatic pathology and noninvasive fibrosis markers. Methods: A total of 246 Japanese patients with NAFLD diagnosed by liver biopsy were enrolled. We investigated their prognosis based on hepatic pathology and noninvasive fibrosis markers. Results: When these patients were categorized based on the severity of liver fibrosis as F0–2 (n = 196) and F3–4 (n = 50), the patients with F3–4 had significantly poorer prognosis in overall survival rates and all complications (P < 0.05). The fibrosis‐4 (FIB‐4) index was useful to predict overall survival and the incidence of hepatocellular carcinoma and liver cirrhosis (LC)‐related complications but not extrahepatic malignancies. Multiple logistic regression analyses revealed the following risk factors: total bilirubin ≥ 1.2 (hazard ratio [HR] 6.362, 95% confidence interval [CI] 1.393–29.052) and severe liver fibrosis (HR 6.512, 95% CI 1.433–29.592) for overall survival; liver fibrosis (F3–4) (HR 13.370, 95% CI 2.775–64.427) for hepatocellular carcinoma; FIB‐4 index (HR 26.560, 95% CI 3.320–212.494) for LC‐related complications, and liver inflammation (A2–3) (HR 4.214, 95% CI 1.354–13.116) for extrahepatic malignancies. Conclusions: Severe liver fibrosis was associated not only with the hepatocarcinogenesis and LC‐related complications but also with extrahepatic malignancies. The FIB‐4 index was useful for predicting liver‐related diseases but had limitations in predicting extrahepatic malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jgh.14448

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 41

Metadata

Authors
Ito, T., Ishigami, M., Ishizu, Y., Kuzuya, T., Honda, T., Hayashi, K., Nishimura, D., Toyoda, H., Kumada, T., Goto, H., & Hirooka, Y.
Venue
Journal of Gastroenterology and Hepatology
Publisher
Wiley
Published
2018-09-18
Volume
34
Issue
1
Pages
207-214
ISSN
  • 0815-9319 (ISSN-L)
  • 1440-1746
OpenAlex
W2888519594
Cited by
41
References
9
FWCI
3.24
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy‐proven Japanese non‐alcoholic fatty liver disease patients. https://app.cochat.ai/papers/10.1111/jgh.14448
The paper
Ito, T., Ishigami, M., Ishizu, Y., Kuzuya, T., Honda, T., Hayashi, K., Nishimura, D., Toyoda, H., Kumada, T., Goto, H., & Hirooka, Y. (2019). Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy‐proven Japanese non‐alcoholic fatty liver disease patients. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.14448

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.